The Rise of Pan-Resistant Gram-Negatives: Are We Running Out of Options? Review Abstract Pan-resistant gram-negative bacteria represent one of the most pressing challenges in modern medicine. These organisms exhibit resistance to virtually all available antimicrobial agents, leaving clinicians with extremely limited therapeutic options. This paper
Internal Medicine
Reimagining Code Status in the 80+ Population: Beyond ‘Full Code’ vs ‘DNR.’
Reimagining Code Status in the 80+ Population: Beyond ‘Full Code’ vs ‘DNR.’ Review Abstract The traditional binary approach to code status decisions in patients over 80 years old fails to address the complex medical and ethical considerations inherent in this vulnerable population. This paper examines
Ozempic Nation: Paradigm Shift or Public Health Mirage?
Ozempic Nation Paradigm Shift or Public Health Mirage Review Abstract The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies has transformed the management of obesity and type 2 diabetes mellitus. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, initiated a major shift in
IBS Next-Generation Therapies: Low FODMAP Diets, Neuromodulators, Digital Cognitive Behavioral Therapy, and Microbiome-Based Interventions
IBS Next-Generation Therapies: Low FODMAP Diets, Neuromodulators, Digital Cognitive Behavioral Therapy, and Microbiome-Based Interventions Review Abstract Background Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by abdominal pain associated with altered bowel habits. Conventional therapies often provide incomplete symptom relief, leading to
Contemporary Lipid Management in Family Practice: Risk Stratification, Coronary Artery Calcium, and Shared Decision-Making for Statin Therapy
Contemporary Lipid Management in Family Practice: Risk Stratification, Coronary Artery Calcium, and Shared Decision-Making for Statin Therapy Review Abstract Purpose: This paper examines current approaches to lipid management in family practice, focusing on risk stratification methods, the role of coronary artery calcium scoring, and implementation of
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden Review Abstract Lipidology is undergoing a clinically important transition from traditional cholesterol-centered assessment toward a more precise evaluation of atherogenic lipoprotein burden. Low-density lipoprotein cholesterol (LDL-C) remains a validated therapeutic target
UTI Care: When to Treat Symptoms, When to Culture, Recurrent UTI Pathways
UTI Care: When to Treat Symptoms, When to Culture, Recurrent UTI Pathways Review Abstract Urinary tract infections (UTIs) are among the most common bacterial infections encountered in clinical practice, affecting millions of patients annually. This paper examines evidence-based approaches to UTI management, focusing on three
Biologics in Pregnancy and Lactation: How Aggressive Can We Safely Be?
Biologics in Pregnancy and Lactation: How Aggressive Can We Safely Be? Review Abstract Biologic therapies have transformed the management of chronic inflammatory and autoimmune diseases by targeting specific components of the immune system. Their use has led to significant improvements in disease control, quality of life, and
The Vitamin D Debate: From Universal Supplement to Precision Therapy
The Vitamin D Debate: From Universal Supplement to Precision Therapy Review Abstract Vitamin D supplementation has evolved from a simple solution to rickets into one of medicine’s most debated therapeutic interventions. This paper examines the current evidence surrounding vitamin D’s role in health and disease,
The Return of Old Antibiotics: Are Colistin and Fosfomycin Making a Comeback?
The Return of Old Antibiotics: Are Colistin and Fosfomycin Making a Comeback? Review Abstract The rise of multidrug-resistant bacterial infections has forced clinicians to reconsider older antimicrobial agents previously abandoned due to toxicity concerns. Colistin and fosfomycin, antibiotics discovered decades ago, have experienced renewed clinical
